Travere Therapeutics (RTRX) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free RTRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To Knowmarkets.businessinsider.com - April 17 at 4:04 PMTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyrealmoney.thestreet.com - February 23 at 3:07 PMTravere Therapeutics gains as EU backs kidney disease therapymsn.com - February 23 at 8:37 AMNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?msn.com - February 21 at 8:05 AMTravere Therapeutics price target raised by $4 at Citi, here's whyrealmoney.thestreet.com - February 17 at 7:51 AMTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market Competitionmarkets.businessinsider.com - February 16 at 10:57 AMEarnings Preview For Travere Therapeuticsbenzinga.com - February 14 at 4:00 PMTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market Prospectsmarkets.businessinsider.com - January 11 at 7:54 AMOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic Reorganizationmarkets.businessinsider.com - December 7 at 5:53 PMTravere (TVTX) Up on Latest Portfolio Updates & Reorganizationmsn.com - December 6 at 5:04 PMBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic Reorganizationmarkets.businessinsider.com - December 5 at 8:07 PMTravere Therapeutics upgraded to Buy from Neutral at Citirealmoney.thestreet.com - December 5 at 2:51 PMTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatmentsmarketwatch.com - December 4 at 8:55 PMTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conferencebenzinga.com - November 21 at 6:25 PMPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere Therapeuticsmarkets.businessinsider.com - November 8 at 3:32 PMPreview: Travere Therapeutics's Earningsbenzinga.com - November 6 at 2:56 PMTravere Therapeutics Inc Ordinary Shares TVTXmorningstar.com - October 31 at 6:21 PMWedbush Reiterates Travere Therapeutics (TVTX) Outperform Recommendationmsn.com - September 30 at 10:26 AMWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Lowmsn.com - September 22 at 5:07 PMWhy Shares of Travere Therapeutics Are Slumping Thursdaymsn.com - September 21 at 3:15 PMBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challengesmarkets.businessinsider.com - September 21 at 3:15 PMBank of America Securities Remains a Buy on Travere Therapeutics (TVTX)markets.businessinsider.com - August 31 at 7:43 AMMirum Pharmaceuticals to Buy Bile Acid Product Portfolio from Travere Therapeuticsmarketwatch.com - July 19 at 8:02 PMTVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Lawsbenzinga.com - June 26 at 8:57 AMEvercore ISI Group Maintains Travere Therapeutics (TVTX) Outperform Recommendationmsn.com - May 3 at 10:28 AMTravere Therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drugmsn.com - May 2 at 12:58 PMTravere Therapeutics (TVTX) Gets a Buy from SVB Securitiesmarkets.businessinsider.com - April 14 at 2:07 AMQ4 2022 Travere Therapeutics Inc Earnings Callfinance.yahoo.com - February 26 at 12:24 PMTravere Therapeutics, Inc. (TVTX) Q4 2022 Earnings Call Transcriptseekingalpha.com - February 25 at 3:34 PMTravere Therapeutics's Earnings Outlookbenzinga.com - February 22 at 4:05 PMWhat 10 Analyst Ratings Have To Say About Travere Therapeuticsmsn.com - February 22 at 10:54 AMTravere Therapeutics Shares Climb 21% on FDA Accelerated Approval of Filsparimarketwatch.com - February 21 at 2:05 PMTravere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatmentmsn.com - February 21 at 9:05 AMU.S. FDA approves Travere Therapeutics' kidney disorder drugreuters.com - February 19 at 11:41 PMTravere Therapeutics Earnings Perspective: Return On Capital Employedbenzinga.com - November 3 at 11:00 AMTravere Therapeutics Provides Regulatory Updates on its Development Programstmcnet.com - August 3 at 7:34 PMWhere Travere Therapeutics Stands With Analystsmsn.com - July 26 at 1:36 PM‘Call Me Kat’ Renewed for Season 3 by Foxyahoo.com - May 18 at 3:26 PMBuffalo shooting suspect duped by 'replacement theory' that's now part of the GOP playbookyahoo.com - May 18 at 12:04 AMHC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - May 17 at 5:23 PMTravere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congressfinance.yahoo.com - May 17 at 5:23 PMAnalyst Ratings for Travere Therapeuticsmarkets.businessinsider.com - May 17 at 5:23 PMTravere Therapeutics Enters Oversold Territory (TVTX)nasdaq.com - May 9 at 11:28 PMTravere Therapeutics' (TVTX) CEO Eric Dube on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 8 at 5:05 AM Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> RTRX Media Mentions By Week RTRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RTRX News Sentiment▼0.000.32▲Average Medical News Sentiment RTRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RTRX Articles This Week▼00▲RTRX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kamada News Neoleukin Therapeutics News Erasca News Verrica Pharmaceuticals News Renovaro News CorMedix News Akebia Therapeutics News ESSA Pharma News Terns Pharmaceuticals News XOMA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RTRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
